You are here: Industry Insights > GW

News List

MHRA approves for Epidyolex® (cannabidiol) for TSC seizure treatment europeanpharmaceuticalreview
August 13, 2021
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
UK approval for Epidyolex to treat seizures from tuberous sclerosis pharmatimes
August 11, 2021
Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis ...
Highest British business award goes to cannabis drug developer, GW Pharmaceuticals europeanpharmaceuticalreview
April 30, 2021
The Queen’s Award for Enterprise in Innovation was awarded to GW for leadership in cannabinoid science and development of prescription cannabis-based medicines.
GW Pharmaceuticals Receives European Commission Approval for EPIDYOLEX® (cannabidiol) for the Treatment of Seizures Associated with Tuberous Sclerosis Complex americanpharmaceuticalreview
April 21, 2021
GW Pharmaceuticals plc, a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® ...
GW Receives Positive CHMP Opinion for EPIDYOLEX for TSC Seizures americanpharmaceuticalreview
March 04, 2021
GW Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive ...
Jazz Pharma to buy GW Pharma for $7.2 billion, adding cannabis-based drug to portfolio expresspharma
February 04, 2021
The deal will allow Jazz to move beyond sleep disorders and cancer treatments by beefing up its neuroscience unit.
NICE to work with GW Pharma on cannabidiol evaluation europeanpharmaceuticalreview
August 29, 2019
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
Key European committee backs GW's Epidyolex, Bayer's Vitrakvi and more fiercepharma
July 28, 2019
In a busy meeting this week, experts with the European Medicines Agency's Committee for Medicinal Products for Human Use endorsed four new drugs, a Mylan generic, and numerous new indications for already-marketed meds.
GW launches cannabis-based epilepsy drug in US pharmaphorum
November 30, 2018
GW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare form of childhood epilepsy.
FDA greenlights GW's Epidiolex, the first U.S. drug made from marijuana fiercepharma
June 26, 2018
The FDA just approved Epidiolex, the GW Pharma seizure drug derived from cannabis, giving children with two rare and serious forms of epilepsy a new treatment...

Previous page 1 2 Next page